The partnership will combine Geisinger’s decades’ worth of clinical data with Tempus’ machine learning technology. The Tempus AI will analyze Geisinger’s data to track patient outcomes and responses, with a goal of developing highly personalized and proactive treatments and interventions for cardiovascular disease.
“Our mission is to improve the lives of patients with cardiovascular disease through the development and application of state-of-the-art technologies,” said Brandon Fornwalt, MD, PhD, co-director of Geisinger’s Cardiac Imaging and Technology Laboratory, where the partnership will be housed. “This collaboration brings together complementary areas of expertise unified behind a joint vision of integrating the best technology available to positively impact our patients.”
More articles on AI:
GE Healthcare’s AI X-ray device 1st to receive FDA clearance
Intel, Nvidia execs say White House plan for $1B AI investment doesn’t go far enough
Geisinger partners with IBM for AI-based sepsis prevention
